Q3 2025 Earnings Call November 4, 2025 Disclaimer Forward-looking Statements Certain statements in this presentation constitute forward-looking statements under federal securities laws. These forward-looking statements reflect our views with respect to future events and financial performance as of the date of this presentation or otherwise specified herein. Actual events and results may differ materially from those contemplated by such forward-looking statements due to risks and other factors that are set f ...

This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, In ...

Q3 2025 earnings November 4, 2025 Forward looking statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to, information or predictions concerning our future financial performance, including our financial outlook for Q4 2025 and the full fiscal year 2025 under the heading "Outlook" and management's estimates under the heading " ...

Q3 2025 Earnings Report © 2025 Pinterest. All rights reserved. Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we use the following non-GAAP financial measures: Adjusted EBITDA, Adjusted EBITDA margin, non-GAAP costs and expenses (including non-GAAP cost of revenue, research and development, sales and marketing, and general and administrative) ...

Third Quarter 2025 Earnings November 4, 2025 1 Safe Harbor Statement Executive Summary | Continuing Operations(1) | Continuing Operations(1) | Executive Summary | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Non-GAAP results including new tariffs: | Non-GAAP results including new tariffs: | Revenue(2) | Revenue(2) | million grew 8% on a constant currency(3) | million grew 8% on a constant currency(3) | • | • | of $371 | of $3 ...

Q3 2025 Financial Highlights November 4, 2025 PAGE 2 Note on Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," or similar expres ...

This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2025 financial outlook, and which may be identified by the use of words like "expects ...

Third Quarter 2025 Financial Results Conference Call November 4, 2025 Matt, an XDEMVY® Patient Today's Speakers Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements and the most recent Form 10-Q quarterly filing filed with the SEC include stateme ...

业绩总结 - 2025年第三季度总净产量为19.7百万桶油当量（MMBoe），日均产量为213.8千桶油当量（MBoe/d），其中油占比超过53%[15] - 2025年第三季度每股GAAP收益为1.35美元，调整后的每股净收益为1.33美元[19] - 2025年第三季度的总收入为727,300千美元[65] - 调整后的EBITDAX为5.882亿美元，调整后的自由现金流为2.343亿美元[15][69] - 2025年第三季度现金生产利润为每Boe 29.59美元[31] 用户数据 - 2025年第三季度油气收入总计811,009千美元，油收入为669,106千美元[31] - 2025年第三季度每桶油的实现销售价格为63.83美元，较基准WTI的溢价为98%[31] - 2025年第三季度天然气的实现销售价格为2.19美元/每千立方英尺，较基准NYMEX Henry Hub的溢价为71%[31] - 2025年第三季度NGL的实现价格为20.79美元/每桶，较OPIS基准的折扣为19%[35] 未来展望 - 预计2025年总净产量指导为207至208 MBoe/d，油占比为53%至54%[26] - 2025年预计净证明储量较2020年增长76%，预计日均总净产量较2020年增长68%[10] - 2025年第四季度资本支出指导为2.25亿至2.45亿美元，全年资本支出指导为13.75亿至13.95亿美元[26] 新产品和新技术研发 - 2025年第三季度在Midland Basin钻探了7口新井，南德克萨斯州钻探了8口新井[34] - 截至2025年9月30日，公司在Midland Basin的净土地面积为107,500英亩[41] 财务状况 - 截至2025年9月30日，净债务为26亿美元，净债务与调整后EBITDAX的比率为1.1倍[21] - 2025年第三季度的生产税占预对冲收入的4.1%[31] - 2025年第三季度净现金提供的经营活动为504,960千[69] 股东回报 - 2025年第三季度支付每股现金股息0.20美元，年化股息收益率为4%[15] - 2025年第三季度回购股票金额为1200万美元，累计回购金额为6.25亿美元[24]

Mirum Pharmaceuticals: Transforming Lives in Rare Disease N o v e m b e r 2 0 2 5 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and opportunities, including the future oppo ...